Skip to content
Jade Biosciences, Inc. Common Stock logo

Jade Biosciences, Inc. Common Stock

JBIO

Jade Biosciences, Inc. Common Stock is a pharmaceutical preparations company trading on NASDAQ, led by CEO Tom Frohlich, with a market cap of $1.3B.

Market cap
$1.33B+318%
Net income-$129.6M-27.1%
Free cash flow-$94.9M-66.7%
EPS (diluted)-$2.02+93.8%
Trailing twelve months · change vs. prior year

Table of contents

Earnings

Next report

Aug 12, 2026 (in 2 months)
EPS estimate-$0.66

Financials

Q1 2026

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation & ratios

Valuation

See full
Market cap$1.33B
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Profile

Questions, answered.

What is Jade Biosciences, Inc. Common Stock's market cap?
Jade Biosciences, Inc. Common Stock (JBIO) has a market capitalization of $1.3B and trades on NASDAQ.
Where is Jade Biosciences, Inc. Common Stock headquartered?
Jade Biosciences, Inc. Common Stock is headquartered in United States of America. It has been publicly traded since 2025.